Last reviewed 2026-05-28 · How we verify

Tubes 3~5Tablet, QD

LigaChem Biosciences, Inc. · Phase 2 active Small molecule ✓ Verified May 2026

Tubes 3~5Tablet, QD is a Small molecule drug developed by LigaChem Biosciences, Inc.. It is currently in Phase 2 development. Also known as: Tubes Tablet.

Tubes 3-5 Tablet, taken once daily at a dose of 800mg, is being studied in a Phase II clinical trial for the treatment of Pulmonary Tuberculosis. The trial, NCT02836483, is evaluating the efficacy, safety, and pharmacokinetics of LCB01-0371 in this patient population.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	Tubes 3~5Tablet, QD
Also known as	Tubes Tablet
Sponsor	LigaChem Biosciences, Inc.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Phase II Clinical Study of LCB01-0371 to Evaluate the EBA, Safety and PK (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Tubes 3~5Tablet, QD CI brief — competitive landscape report
Tubes 3~5Tablet, QD updates RSS · CI watch RSS
LigaChem Biosciences, Inc. portfolio CI

Frequently asked questions about Tubes 3~5Tablet, QD

What is Tubes 3~5Tablet, QD?

Tubes 3~5Tablet, QD is a Small molecule drug developed by LigaChem Biosciences, Inc..

Who makes Tubes 3~5Tablet, QD?

Tubes 3~5Tablet, QD is developed by LigaChem Biosciences, Inc. (see full LigaChem Biosciences, Inc. pipeline at /company/ligachem-biosciences-inc).

Is Tubes 3~5Tablet, QD also known as anything else?

Tubes 3~5Tablet, QD is also known as Tubes Tablet.

What development phase is Tubes 3~5Tablet, QD in?

Tubes 3~5Tablet, QD is in Phase 2.

Manufacturer: LigaChem Biosciences, Inc. — full pipeline
Also known as: Tubes Tablet

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing